Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
- 30 June 2008
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 109 (3), 329-334
- https://doi.org/10.1016/j.ygyno.2008.03.010
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group studyGynecologic Oncology, 2007
- Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxelInvestigational New Drugs, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic StudyJournal of Clinical Oncology, 2005
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- Trimetrexate in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus: A Phase II Study of the Gynecologic Oncology GroupGynecologic Oncology, 2002
- Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 1998
- Phase II Trial of Etoposide in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996